Guggenheim Capital LLC Akero Therapeutics, Inc. Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 25,198 shares of AKRO stock, worth $719,654. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,198
Previous 31,903
21.02%
Holding current value
$719,654
Previous $748,000
3.48%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$226 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$202 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$169 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$160 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$149 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.33B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...